Utility values (see Table Table4)4) are based on a study by Czoski-Murray et al. conducted in the UK which estimated a regression model to relate visual acuity score and utility on the basis of time trade-off methods, including an age covariate [40]. A further adjustment was applied to account for better vision in one eye, partially compensating for worse vision in the other. Aligned with the approach in a guideline review conducted by NICE in nAMD [20], a scaling factor of 0.3 is used to estimate the impact of changes in the worse seeing eye on utility. A disutility for injections and adverse events was included in the model. It was assumed that 50% of patients experience a total loss of quality of life on treatment days, informed by the same UK guideline [20].
Health state utility scores by visual acuity and first/second eye
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.